Anti-BCMA CAR Lentivirus (VHH1/VHH2 ScFv-CD8-4-1BB-CD3ζ)

Catalog #

78783

$1,095 *

Size: 50 µl

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

The anti-BCMA CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to transduce most mammalian cells, including primary and non-dividing cells. These viruses transduce cells with the ScFv (single-chain variable fragment) that recognizes two BCMA epitopes (clones VHH1 and VHH2), linked to a CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains. The lentiviruses also include a puromycin selection marker (Figure 1).

Figure 1. (A) Schematic of the lenti-vector used to generate the anti-BCMA CAR lentivirus. The vector is a SIN vector, and it contains a puromycin selection marker. (B) Construct diagram showing components of the anti-BCMA CAR.

●

Product Data Gallery

Expression of anti-BCMA CAR in T cells transduced with anti-BCMA CAR lentivirus.

Cytotoxicity profile of T Cells transduced with anti-BCMA CAR lentivirus against Firefly Luciferase RPMI 8226 target cells.

Product Info

Storage and Usage

Citations

Supplied As

50 µl of anti-BCMA CAR Lentivirus at a titer ≥3x10⁸ TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.

Materials Required But Not Supplied

Name	Ordering Information
PBMC, Frozen	BPS Bioscience #79059
Human Interleukin-2	BPS Bioscience #90184
EasySep™ Human CD4⁺ T Cell Isolation Kit	Stemcell Technologies #17952
EasySep™ Human CD8⁺ T Cell Isolation Kit	Stemcell Technologies #17953
Human CD3/CD28/CD2 T Cell Activator	Stemcell Technologies #10970
BCMA, Fc-Fusion, Avi-Tag, PE-Labeled Recombinant	BPS Bioscience #100733
Firefly Luciferase K562 Recombinant Cell Line	BPS Bioscience #78621
Firefly Luciferase-RPMI 8226 Recombinant Cell Line	BPS Bioscience #79834
ONE-Step™ Luciferase Assay System	BPS Bioscience #60690

Formulation

The lentiviruses were produced from HEK293T cells, concentrated and resuspended in DMEM. Virus particles can be packaged in custom formulations by special request, for an additional fee.

Background

B-cell maturation antigen (BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF) and is involved in B cell proliferation and maturation. BCMA is preferentially expressed in mature B lymphocytes and the soluble form of BCMA can be found at higher levels in the serum of Multiple Myeloma (MM) patients. BCMA is a highly attractive target antigen for immunotherapy. BCMA, similarly to CD19, is restricted in expression to mature B cells allowing the progenitor’s population to be spared during treatment and to replenish the patient’s B cell population. BMCA targeting therapies include bispecific antibodies, antibody-drug conjugates and chimeric antigen receptor (CAR) T cells. To date, the FDA has approved two BCMA CAR-T therapies for the treatment of MM, that resulted in promising outcomes for patients. Further studies will allow a better understanding of the role of BCMA in cancer and fine tune cancer therapy tools.

Storage/Stability

Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C for up to 12 months from date of receipt. Avoid repeated freeze/thaw cycles. Titers can drop significantly with each freeze/thaw cycle.

Growth Media

T Cell Medium: TCellM™ (BPS Bioscience #78753) supplemented with 10 ng/ml Interleukin-2 (BPS Bioscience #90184).

Media required for the Proposed Assay
Thaw Medium 2 (BPS Bioscience #60184): RPMI 1640 medium supplemented with 10% FBS, 1% Penicillin/Streptomycin

Applications

Positive control for anti-BCMA CAR evaluation in immune cells.
Transduction optimization studies.

Shipping Temperature

-80°C

Notes

Biosafety
The lentiviruses are produced with a SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.

Troubleshooting Guide
Visit bpsbioscience.com/lentivirus-faq for detailed troubleshooting instructions. For all further questions, please email [email protected].

Warnings

Avoid freeze/thaw cycles

Scientific Category

Cancer Therapy Target

Regulatory Status

Research Use Only

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Anti-BCMA CAR Lentivirus (VHH1/VHH2 ScFv-CD8-4-1BB-CD3ζ)

PRODUCTS

SERVICES

RESOURCES

COMPANY